A Commitment to Diversity and Inclusivity in Cancer Clinical Trials

Clinical trials evaluate the efficacy, safety, and effectiveness of clinical treatments and devices, including drugs, surgeries, diets, behavioral approaches, and lifestyle interventions seeking to improve individual and community health. To account for the diverse lived experiences and exposures of various populations, clinical trials must be appropriately inclusive of racial and ethnic minority groups, as well as other populations experiencing health disparities, including sexual and gender minority or socioeconomically disadvantaged populations. 

$2Million Grant from Merck Foundation September 2022

$2Million Grant from Merck Foundation to Advance Equitable Cancer Care in New Jersey

RWJBarnabas Health, in partnership with Rutgers Cancer Institute of New Jersey, announced it is a grantee supported through the Alliance for Equity in Cancer Care, funded by the Merck Foundation and designed to make cancer care more equitable in the United States by helping patients living in underserved communities receive timely access to high-quality, culturally responsive care.

Welcoming Dr. Matasar

Welcoming the New Chief of Blood Disorders

Matthew Matasar, MD, MS, has been named Chief of Blood Disorders at New Jersey’s leading cancer center and the only one in the state designated as a Comprehensive Cancer Center by the National Cancer Institute. In this role, he will oversee the Sections of Hematologic Malignancies; Transplant and Cell Therapy; and Benign Hematology. Read more